De Novo Metastatic Prostate Cancer: Are We Moving toward a Personalized Treatment?

SIMPLE SUMMARY: De novo metastatic hormone-sensitive prostate cancer usually has a dismal prognosis, which has slightly improved in recent years thanks to the introduction of new hormonal agents and chemotherapy combined with androgen deprivation therapy from the first-line setting. The randomized c...

Descripción completa

Detalles Bibliográficos
Autores principales: Piombino, Claudia, Oltrecolli, Marco, Tonni, Elena, Pirola, Marta, Matranga, Rossana, Baldessari, Cinza, Pipitone, Stefania, Dominici, Massimo, Sabbatini, Roberto, Vitale, Maria Giuseppa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10605467/
https://www.ncbi.nlm.nih.gov/pubmed/37894312
http://dx.doi.org/10.3390/cancers15204945

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10605467/
https://www.ncbi.nlm.nih.gov/pubmed/37894312
http://dx.doi.org/10.3390/cancers15204945

Ejemplares similares